Oral dissolvable strips (ODS) as new pediatric and adult delivery mode of therapy for latent tuberculosis
Ended Project Grant Awarded Last action
- Award ID
- R43AI179391
- Recipient
-
Oak Therapeutics Inc. UEI SJ7GGFACQTJ5
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $260,092
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date
- Originally
- Place of performance
- Kansas, USA
Award details come from USAspending.gov.
Description
- Abstract
- Tuberculosis (TB) remains one of the major sources of mortality from infectious diseases worldwide. In 2021 an estimated 6.4 million were newly diagnosed with TB globally, approximately 10.6 million fell ILL from IT, and 1.4 million died from the disease. Of those who died from the disease, 54% were men, 32% women, and 14% were children aged
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | -$13,366 | |
| Original award | $273,458 |
Quick answers
Who received award R43AI179391?
R43AI179391 was awarded to Oak Therapeutics Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 1, 2023.
How much is award R43AI179391 worth?
$260,092 has been obligated on R43AI179391.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award